We had two aims: (1) to evaluate vaccine efficacy in the immunoprevention of huHER2-driven mammary tumors, and (2) to study whether anti-HER2 antibodies resulting from a break of tolerance could inhibit human tumors growing as xenografts. This evidence concerns the gene ERBB2 and breast cancer.